These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9892684)

  • 1. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
    Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
    Miwa T; Zhou L; Hilliard B; Molina H; Song WC
    Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
    Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
    Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
    Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
    Harris CL; Spiller OB; Morgan BP
    Immunology; 2000 Aug; 100(4):462-70. PubMed ID: 10929073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
    Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
    Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of the PNH defect by GPI-anchored protein transfer.
    Sloand EM; Maciejewski JP; Dunn D; Moss J; Brewer B; Kirby M; Young NS
    Blood; 1998 Dec; 92(11):4439-45. PubMed ID: 9834251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor.
    Molina H; Miwa T; Zhou L; Hilliard B; Mastellos D; Maldonado MA; Lambris JD; Song WC
    Blood; 2002 Dec; 100(13):4544-9. PubMed ID: 12393518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.
    Miwa T; Sun X; Ohta R; Okada N; Harris CL; Morgan BP; Song WC
    Immunology; 2001 Oct; 104(2):207-14. PubMed ID: 11683961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria.
    Telen MJ
    Transfus Clin Biol; 1995; 2(4):277-90. PubMed ID: 8542026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis.
    Sogabe H; Nangaku M; Ishibashi Y; Wada T; Fujita T; Sun X; Miwa T; Madaio MP; Song WC
    J Immunol; 2001 Sep; 167(5):2791-7. PubMed ID: 11509624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor).
    Merry AH; Rawlinson VI; Uchikawa M; Daha MR; Sim RB
    Br J Haematol; 1989 Oct; 73(2):248-53. PubMed ID: 2479410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
    Medof ME; Kinoshita T; Silber R; Nussenzweig V
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor.
    Kinoshita T
    Semin Hematol; 2018 Jul; 55(3):136-140. PubMed ID: 30032750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
    Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
    J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes.
    Ohta R; Imai M; Fukuoka Y; Miwa T; Okada N; Okada H
    Microbiol Immunol; 1999; 43(11):1045-56. PubMed ID: 10609614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
    Parker CJ; Wiedmer T; Sims PJ; Rosse WF
    J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.